Schwab Network on $LLY (Nov 13, 2026)
Eli Lilly is a premium growth story: up 35% in a great year and one of the leaders of the healthcare run, it has capitalized on the biggest healthcare opportunity through its three leading GLP1 products, with favorable demographics a continued tailwind to a strong pipeline, so the premium valuation is justified.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
Eli Lilly is one of those names on your list. I'm betting this is a bet on the GLP1 space, but walk us through your thesis here. Exactly. You know, Eli Lilly's had a great year up 35% and really one of the leaders of that healthcare run.
As you mentioned, they've been able to capitalize on, you know, really the the biggest opportunity right now in healthcare with their three leading GLP1 products.
Um you know, beyond that, I think they have favorable demographics that continue to be tailwinds to their strong pipeline. Um you know, I I think it's worth noting, you know, you're paying a premium for this stock, but I do believe it's a a premium growth story.
What this channel has said about $LLY
Schwab Network has 7 calls on this stock; only the adjacent ones are shown.